United States: Developments In Securities Fraud Class Actions Against U.S. Life Sciences Companies - Dechert

Last year marked an increase in federal securities class action filings, with plaintiffs filing 213 cases in 2023, up from 197 in 2022 and ending an overall decline in filings since 2019.